National Cancer Institute (nci)

This early-phase trial tested whether adding nilotinib (a pill) to paclitaxel (a chemotherapy) is safe and tolerable for people with advanced solid tumors that no longer respond to standard treatments. The study included 47 adults and children aged 12 and older. Researchers aimed…

This study tests a combination of three immunotherapy drugs—PDS0101, M7824, and NHS-IL12—in people with advanced HPV-related cancers such as cervical, anal, and throat cancers. The goal is to see if the mix can shrink tumors or stop them from growing. Participants receive the dru…

This early-phase study tested a new approach for people whose B-cell cancers (like lymphoma or leukemia) came back after a donor stem cell transplant. Researchers took white blood cells from the original donor, genetically modified them to recognize and attack cancer cells, and g…

This study tests a treatment plan tailored to each child's risk level for a rare liver cancer called hepatoblastoma. About 236 children will receive standard treatments like surgery and chemotherapy, plus the drug temsirolimus for high-risk cases. The goal is to see if this appro…

This trial investigates a combination of two drugs: EP0057, a chemotherapy drug wrapped in a nanoparticle to help it reach cancer cells, and olaparib, which stops cancer cells from fixing DNA damage. The study includes adults with small cell lung cancer, bladder cancer, or prosta…

This phase 2 trial tested whether adding carboplatin and/or bevacizumab to standard chemotherapy before surgery helps shrink tumors in people with a hard-to-treat type of breast cancer (hormone receptor-poor, HER2-negative, including triple-negative). 454 participants received we…

This phase 3 trial tested whether a yeast-derived immune stimulant (GM-CSF) and a peptide vaccine, alone or together, could prevent melanoma from returning after surgery. 815 patients with no visible cancer after complete surgical removal of advanced melanoma were randomly assign…

This large phase III trial tested whether adding bevacizumab (Avastin) to standard chemotherapy after complete lung cancer surgery could help patients live longer. Over 1,500 patients with stage IB to IIIA non-small cell lung cancer took part. The study found that adding bevacizu…

This phase 3 trial tested whether adding bevacizumab (Avastin) to standard chemotherapy (gemcitabine and cisplatin) helps people with advanced urinary tract cancer live longer. 506 patients with cancer that had spread or could not be removed by surgery took part. The study compar…

This phase 2 trial tested a combination of two drugs—paclitaxel (given intravenously and directly into the abdomen) and oral nilotinib—in 21 adults with cancers that had spread to the lining of the abdomen and could not be surgically removed. The goal was to see if the treatment …

This phase 3 trial tested the safety of giving a monoclonal antibody (dinutuximab) along with immune-boosting drugs and a vitamin-like drug to children with high-risk neuroblastoma after a stem cell transplant. The goal was to see if this combination could be given safely and hel…

This phase II trial studied 168 people with extensive-stage small cell lung cancer. Researchers added either vismodegib or cixutumumab to standard chemotherapy (cisplatin and etoposide) to see if these combinations worked better than chemo alone. The goal was to slow cancer growt…

This large phase 3 trial studied nearly 1,900 children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Researchers compared different chemotherapy combinations, including varying doses of methotrexate and adding the drug…

This large phase III trial tests which of three chemotherapy drugs—paclitaxel, nab-paclitaxel, or ixabepilone—works best, with or without the targeted drug bevacizumab, for people with stage IIIC or IV breast cancer that has returned or spread. The study aims to find the most eff…

This study tested whether adding veliparib (a PARP inhibitor) to standard chemotherapy (cisplatin and etoposide) helps people with extensive stage small cell lung cancer or certain other lung cancers that have spread. In the first phase, researchers found the best dose of velipar…

This large phase III trial studied whether adding the targeted drug cetuximab to standard chemotherapy after surgery helps prevent cancer from coming back in patients with stage III colon cancer. Over 3,300 patients took part, and the study focused on those with a specific geneti…

This Phase 3 trial tested the drug sorafenib in 87 people with desmoid tumors, a rare type of growth that can be painful and invasive. The study compared sorafenib to a placebo to see if it could slow tumor progression. Sorafenib works by blocking proteins that help tumors grow. …

This study tested whether adding the chemotherapy drug doxorubicin to the targeted therapy sorafenib helps people with advanced liver cancer live longer. Over 350 patients received either sorafenib alone or sorafenib plus doxorubicin. The main goal was to compare overall survival…

This phase III trial tests whether the drug tipifarnib can prevent acute myeloid leukemia (AML) from coming back in patients who are already in remission. Participants include adults over 60 in first remission, those in second or later remission, or those who achieved remission a…

This large phase 3 trial tested whether taking sorafenib or sunitinib after kidney cancer surgery could prevent the cancer from coming back. Nearly 2000 patients participated. Unfortunately, neither drug improved disease-free survival compared to a placebo, and they caused side e…

This phase III trial investigates whether sunitinib, a drug that blocks tumor blood vessel growth, can help patients with advanced non-small cell lung cancer maintain their response after initial chemotherapy. Participants who did not worsen after four cycles of platinum-based ch…

This study tested whether adding an experimental drug (MK-2206) to the standard hormone therapy bicalutamide can better control prostate cancer in men whose PSA levels are rising after initial treatment. About 108 men with recurrent prostate cancer took part. The goal was to see …

This study looked at adding the drug pazopanib to standard radiation or chemoradiation before surgery for patients with certain soft tissue sarcomas. The goal was to see if the combination is safe and helps shrink tumors more effectively. About 140 adults and children with newly …

This early-phase trial tested two drugs—durvalumab and vicineum—in 15 people with high-grade non-muscle-invasive bladder cancer that had not responded to standard BCG treatment. The goal was to see if the combination is safe and can help the immune system fight the cancer. Partic…

This early-phase trial tested a new gene therapy for multiple myeloma, a blood cancer that often becomes resistant to standard treatments. Researchers took participants' own immune T cells, modified them in the lab to recognize a protein called BCMA on myeloma cells, and infused …

This study looked at adding sunitinib malate (a drug that blocks tumor blood flow) to standard chemotherapy for people with extensive-stage small cell lung cancer. The trial involved 156 participants and aimed to find the best dose and see if maintenance sunitinib after chemo cou…

This phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…

This early-phase trial tested a combination of two chemotherapy drugs (gemcitabine and carboplatin) plus lenalidomide, a drug that blocks blood vessel growth in tumors, in 18 adults with advanced solid tumors, especially urothelial (bladder) cancer. The main goal was to find the …

This early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…

This large phase III trial tested whether adding the targeted drug dasatinib to standard chemotherapy improves outcomes for children and young adults with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (B-ALL), including those with certain genetic mutations. Nearly…

This study tested whether adding a drug called oblimersen to standard chemotherapy (daunorubicin and cytarabine) helps older adults (60+) with untreated acute myeloid leukemia live longer or achieve remission. About 500 participants were randomly assigned to receive chemo with or…

This phase III trial tested whether adding trastuzumab (Herceptin) to standard chemotherapy and radiation helps people with HER2-positive esophageal cancer. 203 patients were randomly assigned to get chemo and radiation with or without trastuzumab. The study measured how long pat…

This study tested whether adding two immunotherapy drugs (dinutuximab and GM-CSF) to standard chemotherapy is safe and doable for children newly diagnosed with high-risk neuroblastoma. Forty-two children took part. The goal was to see if the extra drugs cause too many side effect…

This study tested whether giving the immunotherapy drug durvalumab alongside radiation works better than the standard cetuximab plus radiation for people with advanced head and neck cancer who cannot take the usual chemotherapy drug cisplatin. A total of 196 adults took part. The…

This large phase III trial tested whether adding the drugs bortezomib and sorafenib to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) live longer without the cancer returning. Over 1,600 participants took part. The study focused on patients w…

This phase III trial tested whether adding a monoclonal antibody called edrecolomab to surgery helps people with stage II colon cancer live longer or stay cancer-free longer. About 2,100 participants were randomly assigned to receive either the antibody or no additional treatment…

This phase II trial tested a combination of three treatments: specially engineered natural killer cells (PD-L1 CAR-NK cells), an immunotherapy drug (pembrolizumab), and an immune booster (N-803) in 18 adults with advanced gastric or head and neck cancer that had not responded to …

This large Phase III trial tested whether adding the drug bevacizumab to chemotherapy works better when the chemo is given into a vein (IV) or directly into the belly (IP). It involved 1560 people with advanced ovarian, fallopian tube, or peritoneal cancers. The goal was to see w…

This early-phase trial tested a shorter course of radiation for men whose prostate cancer came back after their prostate was removed. Instead of the usual 6-7 weeks of daily radiation, researchers gave higher doses over just 2-4 weeks, focusing the strongest radiation on the tumo…

This early-phase trial tested whether giving activated natural killer (NK) cells, with or without a protein called rhIL15, is safe and feasible for children and young adults with solid tumors that didn't respond to other treatments. Sixteen participants received chemotherapy to l…

This study tested a combination of three hormone-blocking drugs (enzalutamide, abiraterone, and standard hormone therapy) given before surgery in 12 men with newly diagnosed prostate cancer that hasn't spread. Researchers also used special PET/CT scans with a new tracer to see if…

This phase 2 trial tested whether adding the drug veliparib to standard chemotherapy (FOLFIRI) helps people with metastatic pancreatic cancer live longer. 123 patients whose cancer had returned after initial treatment were randomly assigned to get FOLFIRI alone or FOLFIRI plus ve…

This phase II trial tested whether adding stereotactic body radiation therapy (SBRT) to the immunotherapy drug pembrolizumab (Keytruda) works better than pembrolizumab alone for advanced Merkel cell carcinoma, a rare and aggressive skin cancer. Nine patients with metastatic disea…

This early-phase trial tested a combination of two cancer drugs, bortezomib and clofarabine, in 28 adults with advanced solid tumors, lymphomas, or myelodysplastic syndromes that had stopped responding to standard therapy. The main goal was to find the safest dose and check for s…

This study tested whether adding a prostate cancer vaccine (PROSTVAC) and chemotherapy (docetaxel) to standard hormone therapy works better than hormone therapy alone for men whose prostate cancer has spread. 74 men with metastatic castration-sensitive prostate cancer took part. …

This early-phase trial tested a new drug called AZD8186 combined with the chemotherapy docetaxel in 23 patients with advanced solid tumors that have PTEN or PIK3CB gene mutations. The main goal was to find the safest dose and understand side effects. The study is complete, but re…

This phase 1 trial tested a new therapy called CD22-CAR T cells in 134 children and young adults (ages 1-39) with B-cell leukemia or lymphoma that had not been cured by standard treatments. The therapy involves taking a patient's own white blood cells, modifying them in a lab to …

This phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…

This study tested whether using PET/CT scans during treatment to adjust radiation plans can improve outcomes for people with stage III non-small cell lung cancer. 138 participants were randomly assigned to receive either standard radiation or radiation guided by mid-treatment sca…

This study compared standard radiation plus chemotherapy to radiation plus two immunotherapy drugs (ipilimumab and nivolumab) in 159 people with a newly diagnosed, aggressive brain cancer called MGMT-unmethylated glioblastoma. The goal was to see if the immunotherapy combination …

This phase 2 trial tested whether adding two immunotherapy drugs (nivolumab and ipilimumab) to standard chemotherapy (temozolomide) improves survival in 47 adults with newly diagnosed glioblastoma or gliosarcoma. Participants had their tumors surgically removed and completed init…

This study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…

This phase 2 trial tested whether adding the drug veliparib to standard chemotherapy (cisplatin) helps people with metastatic triple-negative or BRCA-related breast cancer, including those with brain metastases. The study enrolled 344 participants to see if the combination slows …

This study tested a drug called palbociclib in 23 children and young adults (ages 1–21) whose cancers had come back or didn't respond to treatment. The drug works by blocking proteins that help cancer cells grow. The goal was to see if it could shrink tumors or slow the disease i…

This phase II trial tested whether adding sorafenib to cetuximab works better than cetuximab alone for patients with advanced head and neck cancer that has come back or spread. Fifty-five adults with various types of head and neck cancer took part. The study measured how long pat…

This phase 2 pilot study tested a combination of three drugs—carfilzomib, lenalidomide, and dexamethasone—in 55 people with high-risk smoldering multiple myeloma, a condition that often leads to active myeloma. The goal was to see if the treatment could eliminate signs of the dis…

This trial tested a new therapy for cancers caused by HPV-16, such as cervical, anal, and throat cancers. Researchers took patients' white blood cells, genetically engineered them to recognize a protein called E7 found in HPV cancer cells, and infused them back. Patients also rec…

This study tested whether adding an immunotherapy drug (dinutuximab) and immune-boosting medicines to standard treatment helps children with high-risk neuroblastoma stay cancer-free longer. About 1,400 children who had already received intensive chemotherapy and a stem cell trans…

This early-phase study tested a combination of three drugs (VIP152, venetoclax, and prednisone) in 8 adults with aggressive non-Hodgkin lymphomas that had returned or not responded to prior treatments. The main goals were to check safety and find the best dose, while also measuri…

This large phase III trial tested whether adding the targeted drug erlotinib or chemoradiation to standard chemotherapy after surgery could help people with pancreatic cancer live longer. Over 500 patients who had their tumor removed were randomly assigned to different treatment …

This early-phase trial tested two experimental drugs, FdCyd and THU, taken by mouth for advanced solid tumors that had not responded to standard treatments. Fifty-nine adults received the drugs in 21-day cycles to see if they were safe and tolerable. The goal was to find a dose f…

This phase II trial tested two oral drugs, sunitinib and cediranib, in 34 people with metastatic alveolar soft part sarcoma (ASPS), a rare cancer that has no standard treatment. Participants were randomly assigned to one drug, and if their disease worsened, they could switch to t…

This study tested two drugs, olaparib and ramucirumab, in 51 people with advanced stomach or gastroesophageal junction cancer that had spread or could not be removed. The goal was to find the best dose and see how well the combination worked. The trial is complete, and results ma…

This early-phase trial tested a combination of four drugs (romidepsin, CC-486, dexamethasone, and lenalidomide) in 26 adults with T-cell cancers that had returned or stopped responding to prior treatments. The main goal was to find a safe dose and check for side effects. While th…

This study tested the drug ibrutinib as a first treatment for people newly diagnosed with moderate to severe chronic graft-versus-host disease (cGVHD), a condition where donor cells attack the recipient's body after a stem cell transplant. Ten adults took ibrutinib daily for up t…

This study tested a special pump placed under the skin that sends chemotherapy directly to the liver through the hepatic artery. It was for people with colorectal cancer that had spread to the liver and who had already tried other chemotherapies. The goal was to see if this direc…

This study tested giving a second round of radiation to people whose glioblastoma (a fast-growing brain tumor) came back after standard treatment. Seventeen adults aged 18 to 50 received daily radiation for 2-3 weeks. The goal was to find the safest highest dose and see how it af…

This study tested a shorter course of a chemotherapy combination called EPOCH-R in 68 people with HIV and a type of lymphoma. The goal was to see if reducing the amount of chemotherapy could still control the cancer while causing less damage to the immune system. Participants rec…

This early-stage trial tested an experimental drug called Z-Endoxifen in 40 adults with hormone receptor-positive cancers (like breast, ovarian, or desmoid tumors) that had stopped responding to standard treatments. Z-Endoxifen is a direct form of tamoxifen's active ingredient, b…

This early-phase study tested a new mix of three drugs—IL-15, nivolumab, and ipilimumab—in 31 adults with cancers that no longer respond to standard treatments. The goal was to find the safest dose and see if the combination could help the immune system attack tumors. Participant…

This study tested an experimental treatment for metastatic melanoma using a patient's own immune cells (tumor-infiltrating lymphocytes) grown in a lab and given back along with high-dose IL-2. Before the cell infusion, all patients received chemotherapy to suppress their immune s…

This phase II trial tested whether adding bevacizumab to the immunotherapy drug ipilimumab helps people with advanced melanoma that cannot be removed by surgery. The study enrolled 169 participants and measured overall survival and tumor progression. The goal was to see if the co…

This phase II trial tested whether adding veliparib or pembrolizumab to standard chemotherapy and radiation therapy helps shrink tumors in people with locally advanced rectal cancer. 363 participants received either standard treatment or one of the experimental combinations. The …

This early-stage trial tested a combination of two drugs, lenalidomide and blinatumomab, in 35 adults with non-Hodgkin lymphoma that had come back or stopped responding to treatment. The main goal was to find the safest dose and understand side effects. Researchers also looked at…

This study looked at two different drug combinations for people with a type of blood cancer called follicular lymphoma that had not been treated before. One group received ofatumumab and bendamustine, while the other got those two drugs plus bortezomib. The goal was to see which …

This early-phase trial tested a combination of two drugs—veliparib and temozolomide—in 66 adults with relapsed or refractory acute leukemias. Veliparib blocks a DNA repair enzyme, while temozolomide damages cancer cell DNA. The goal was to find the safest dose and check for side …

This early-phase trial tested whether adding the immunotherapy drug atezolizumab before and during standard chemoradiation could help control advanced cervical cancer that has spread to lymph nodes. Forty participants received the combination to see if it activated the immune sys…

This study tested a drug called trametinib in 260 people with low-grade ovarian or peritoneal cancer that returned or worsened. Trametinib works by blocking certain enzymes that help cancer cells grow. The goal was to see if it works better than standard treatments like hormone t…

This early-phase trial tested two drugs—sapanisertib and ziv-aflibercept—in 83 people with advanced solid tumors that had spread or could not be removed. The goal was to find the safest dose and check for side effects. Sapanisertib blocks enzymes that help cancer cells grow, whil…

This phase II trial tested the drug Minnelide in 16 adults with a rare and aggressive form of pancreatic cancer called adenosquamous carcinoma of the pancreas (ASCP) that had not responded to prior treatments. Participants took Minnelide by mouth daily for 21 days of each 28-day …

This early-phase study tested a highly targeted type of radiation (SBRT) in 17 men whose prostate cancer returned after prior radiation. The goal was to find the highest safe dose and see how well the body tolerated it. Participants received five focused treatments over two weeks…

This study tested a drug called pomalidomide in 34 adults with chronic graft-versus-host disease (GvHD) that didn't improve with standard treatments. GvHD can happen after a stem cell transplant when the donor cells attack the recipient's body. Participants took pomalidomide caps…

This early-phase trial tested a four-drug combination (entinostat, atezolizumab, carboplatin, and etoposide) in 3 people with extensive-stage small cell lung cancer that had not been treated before. The goal was to find a safe dose and see if the combination could be given for at…

This study tested whether the drug palifermin could make stem cell transplants safer and reduce chronic graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. Thirty-four adults with blood cancers received palifermin before transplan…

This study tested different combinations of immunotherapy drugs in 59 adults with advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if these combinations are safe and can help shrink tumors or lower PSA levels. Participants received up to fo…

This phase 2 trial tested the drug cabozantinib in 102 women with endometrial cancer that had returned or spread. The drug works by blocking enzymes that help tumors grow and by cutting off their blood supply. Researchers measured how many patients saw their tumors shrink or stop…

This early-phase trial tested a drug called navtemadlin given alongside radiation therapy before surgery for soft tissue sarcoma. The goal was to find a safe dose and see if the combination could shrink tumors, making surgery easier. 39 patients with intermediate or high-grade sa…

This early-stage trial tested whether adding immunotherapy drugs (durvalumab alone or with monalizumab or oleclumab) to radiation therapy is safe for people with locally advanced non-small cell lung cancer that cannot be removed by surgery. The study enrolled 26 participants and …

This pilot study tested high dose rate brachytherapy, a type of internal radiation, in 43 patients with cervical, endometrial, esophageal, prostate, or biliary cancer. The goal was to see if the radiation implants could deliver the planned dose accurately. Participants received b…

This study followed 40 women at high genetic risk for ovarian cancer due to BRCA mutations or strong family history. One group chose to have their ovaries and fallopian tubes removed to prevent cancer, while the other group opted for regular CA-125 blood tests every 3 months to c…

This study tested whether a very low dose of apalutamide, taken for 3-4 weeks before prostate removal surgery, could lower PSA levels in 34 men with early-stage prostate cancer. The goal was to see if the drug blocks testosterone's effect on cancer growth. If it works, it might o…

This study tested whether a 12-week physical activity program could improve memory and attention in children who had radiation for brain tumors. Thirty-six kids aged 8–17 who finished radiation at least a year ago took part. Half started the program right away, while the other ha…

This study tested whether using a virtual reality (VR) headset at home could help reduce anxiety and distress in adults with primary brain tumors. Sixty-one participants used the VR headset for 4 weeks and filled out symptom questionnaires. The goal was to see if this approach is…

This study looked at whether standard radiation treatment for cancer that has spread to the brain causes changes in thinking skills like memory and attention. 35 adults with brain metastases received radiation and took tests and surveys before and after treatment. The goal was to…

This pilot study tested whether PET-CT scans can detect leukemia that has spread outside the bone marrow in patients with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia (ALL). Ten participants received a PET scan before and after CAR T-cell therapy. The goal was to…

This study followed 17 adults with neurofibromatosis type 1 (NF1) over two years to learn how their skin tumors (dermal neurofibromas) grow and change. Researchers used special cameras and skin biopsies to measure tumor growth and look for genes that might influence it. The goal …

This completed study analyzed leftover tissue samples from 130 people with lymphoma or related conditions. Researchers measured levels of histone and other proteins to find patterns linked to different lymphoma types. The goal was to better understand the biology of these cancers…

This study looks at proteins in the blood of women with ovarian, peritoneal, or fallopian tube cancer who are in remission. The goal is to find a protein pattern, or 'fingerprint,' that signals when the cancer might come back. Researchers followed 119 women with stage III or IV c…

This study tested a document called Voicing My CHOiCES, designed to help young adults (ages 18-39) with serious illnesses like cancer or HIV discuss their care preferences. Participants filled out questionnaires about anxiety, social support, and communication, then reviewed the …

This study looked at people with neurofibromatosis type 1 (NF1) to better understand how harmless tumors (plexiform neurofibromas) turn into a rare cancer called MPNST. Ten participants had MRI, PET scans, and tumor biopsies. Researchers tested whether a special PET scan (FLT PET…

This study reviewed medical records of 730 people who had bone marrow transplants between 2010 and 2015. Researchers wanted to learn how often viral infections happen after transplant and what factors make them more likely. No new treatments were tested; instead, the goal was to …

This completed study enrolled over 50,000 adults aged 40-75 in Iran's Golestan Province to understand why esophageal cancer is so common there. Participants filled out lifestyle and diet questionnaires and provided blood, urine, hair, and nail samples. Researchers are analyzing f…

This completed study enrolled over 1,200 people with brain or spinal cord tumors to collect medical information, blood samples, and tumor tissue. The goal was to better understand these cancers and identify promising areas for future research. Participants also received guidance …

This study tested new screening methods like MRI, duct lavage, and PET scans in 200 women with BRCA gene mutations who are at high risk for breast cancer. The goal was to see if these tools can find cancer earlier than standard mammograms. Participants were followed for three yea…

This study looked at people with three rare genetic conditions—xeroderma pigmentosum (XP), Cockayne syndrome (CS), and trichothiodystrophy (TTD)—that affect the body's ability to repair DNA. Researchers examined 709 participants to understand how these defects relate to cancer ri…

This study looks at people with neurofibromatosis type 1 (NF1) and their families to find out why some have more severe symptoms than others. Researchers will collect medical history, blood samples, and images to study genes and physical traits. The goal is to identify genes that…

This study looked at 629 children in California to see if exposure to pesticides at home or from nearby farms is linked to childhood leukemia. Researchers collected dust from carpets and vacuum cleaners and mapped crops near homes. The goal was to measure chemical levels and see …

This study follows up on over 32,900 people from Linxian, China, who took part in a nutritional trial between 1985 and 1991. Researchers are tracking cancer cases and deaths to see if earlier vitamin and mineral supplements had lasting effects. They are also collecting blood samp…

This study followed 76 children with brain tumors to learn how radiation therapy affects their quality of life, thinking, and body functions over time. Researchers collected blood, urine, and MRI scans before and after treatment, along with tests of memory, behavior, vision, and …

This study looked at nearly 1,900 male farmers over age 50 to see if pesticide exposure is linked to early signs of blood cancers like multiple myeloma. Researchers collected blood and urine samples and compared those with and without exposure to the pesticide diazinon. No treatm…

This study looked back at the medical records of 57 children and young adults (under 25) who received CAR T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL). The goal was to understand how well the treatment worked and what side effects occurred, especially in those w…

This completed study looked at genetic factors that might increase the risk of esophageal and stomach cancers. Researchers collected DNA samples from over 7,700 people, including patients with cancer and healthy individuals from high- and low-risk areas in China. The goal was to …

This study looked at how common BRCA1 and BRCA2 gene mutations are in Hispanic/Latino women with breast cancer. Researchers collected saliva samples and medical history from 266 participants to better understand these mutations in this group. No treatment was given; the goal was …

This study collected and stored biological samples from nearly 10,000 tin miners in China who are at high risk for lung cancer due to workplace exposures. The goal is to use these samples to discover early markers of the disease, which could lead to better screening and preventio…

This completed study enrolled 377 individuals and families with a high risk of breast or ovarian cancer due to known or suspected genetic factors. Researchers collected medical records, questionnaires, and biological samples to better understand the disease's natural history and …

This study aims to understand why testicular cancer sometimes runs in families. Researchers will collect DNA samples and medical information from about 750 people in families with multiple cases of testicular cancer. No treatment is given; the goal is to find genes that increase …

This study collected information from 733 people with a personal or family history of hereditary stomach cancer. The goal was to better understand how these cancers develop and what genes are involved. Participants provided medical history, blood samples, and genetic testing. The…

This study tested whether machine learning can detect cancer pain by analyzing facial expressions, voice, and speech. 83 people with cancer recorded videos at clinic visits and at home over 3 months. The goal was to see if this technology could classify pain levels in a diverse g…

This study gathered information from 326 adults with rare central nervous system tumors, such as medulloblastoma and ependymoma. Participants completed surveys about their symptoms, treatments, and lifestyle, and provided a saliva sample for genetic analysis. The goal was to lear…

This completed study analyzed genetic material from 1,340 patients with lymphoma, leukemia, or multiple myeloma. Researchers used DNA microarrays and other tools to find new molecular subtypes that could explain why some patients respond better to treatment than others. The goal …

This study looked at why some women have dense breasts on mammograms and why that increases their risk of breast cancer. Researchers collected tissue samples, medical records, and health updates from 466 women aged 40-65 who were having a breast biopsy. The goal was to understand…

This study looked at whether newer imaging techniques can better detect when a person with early blood conditions (MGUS or smoldering myeloma) is developing active multiple myeloma. Thirty-one adults with these conditions received three types of scans: a standard PET/CT, an exper…

This completed study collected blood and tumor tissue from 64 patients with advanced cancers (like melanoma, breast, lung, and kidney cancer) to study genetic changes and treatment resistance. The samples are stored for future research, including genomic analysis. No new treatmen…

This study tested whether iPhones and Apple Watches can reliably collect health data from people with cancer. 49 adults undergoing cancer treatment wore an Apple Watch and used an iPhone for 4 months to track activity, fatigue, and thinking skills. The goal was to see if these de…

This study tested whether a mindful self-compassion program could be adapted for young adults aged 18 to 29 with Li-Fraumeni syndrome, a genetic condition that greatly raises cancer risk. Seven participants attended a one-day demonstration and gave feedback on how to make the pro…